Crizotinib has been reported to achieve higher response rate and significantly longer PFS than chemotherapy in large‐scale clinical trials,3, 4 and it has been approved worldwide as a standard therapy for advanced NSCLC patients with ALK oncogene fusion. Here, ALK is linked to non-small cell lung carcinoma.